Abstract | OBJECTIVE:
Tumor necrosis factor-α inhibitors have been available in recent years for treating early and established rheumatoid arthritis (RA). Twice-weekly administration of 25 mg etanercept (ETN) has demonstrated efficacy and safety. The objective of this study was to evaluate the efficacy of once-weekly administration of 50 mg ETN (ETN50), and to compare it with that of twice-weekly administration of 25 mg ETN (ETN25). METHODS: The ETN50 group comprised 29 patients and the ETN25 group 26. The analysis compared changes from baseline in Disease Activity Score in 28 joints (DAS28)-C reactive protein (CRP) and DAS28-erythrocyte sedimentation rate (ESR) between the ETN50 and ETN25 groups. RESULTS: Overall, 42.3 % of ETN50 patients achieved DAS28-ESR remission (<2.6), and 76.9 % experienced low disease activity at 24 weeks. Patients in the ETN50 group also experienced more significant improvement in DAS28-ESR at 4 weeks, higher DAS28-ESR remission rates, and lower disease activity rates than ETN25 group patients. No serious adverse events were experienced in the safety analysis set (ETN50 group). CONCLUSION: These results suggest that ETN50 can lead to earlier remission and higher remission rates compared with ETN25 in patients with RA.
|
Authors | Takeshi Mochizuki, Shigeki Momohara, Koichio Yano, Toshikatsu Shirahata, Katsunori Ikari |
Journal | Modern rheumatology
(Mod Rheumatol)
Vol. 23
Issue 5
Pg. 994-1000
(Sep 2013)
ISSN: 1439-7609 [Electronic] England |
PMID | 23138447
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antirheumatic Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
- Etanercept
|
Topics |
- Aged
- Antirheumatic Agents
(administration & dosage, adverse effects, therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Etanercept
- Female
- Humans
- Immunoglobulin G
(administration & dosage, adverse effects, therapeutic use)
- Male
- Middle Aged
- Receptors, Tumor Necrosis Factor
(administration & dosage, therapeutic use)
- Remission Induction
(methods)
- Retrospective Studies
- Severity of Illness Index
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|